WallStreetZen

NYSE: MRK
Merck & Co Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MRK past earnings growth

How has MRK's earnings growth performed historically?
Company
-30.15%
Industry
14.79%
Market
102.72%
MRK's earnings have grown slower (11% per year) than the US Drug Manufacturers - General industry average (14.81%)
Performance
MRK's earnings have grown slower (11% per year) than the US market average (27.52%)
Performance
MRK's earnings growth is slowing down - its growth over the last year (-30.15%) is below its 5-year compound annual rate (11%)
Performance

MRK past revenue growth

How has MRK's revenue growth performed historically?
Company
-0.13%
Industry
13.32%
Market
36.32%
MRK's revenue has grown slower (4.04% per year) than the US Drug Manufacturers - General industry average (5.13%)
Performance
MRK's revenue has grown slower (4.04% per year) than the US market average (17.66%)
Performance
MRK's revenue growth is slowing down - its growth over the last year (-0.13%) is below its 5-year compound annual rate (4.04%)
Performance

MRK earnings and revenue history

Current Revenue
$48.0B
Current Earnings
$7.0B
Current Profit Margin
14.6%
MRK's has demonstrated consistent long-term earnings growth over the past 10 years (434.62%)
Performance

MRK Return on equity

Current Company
25.8%
Current Industry
31.9%
Current Market
30.7%
MRK's Return on Equity (25.8%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

MRK Return on assets

Current Company
7.7%
Current Industry
6.8%
Current Market
6.4%
MRK is generating higher Return on Assets (7.7%) than the US Drug Manufacturers - General industry average (7.27%)
Performance

MRK Return on capital employed

Current Company
13.02%
Current Industry
11.3%
MRK has gotten more efficient at generating Return on Capital (13.02%) compared to 3 years ago (8.45%)
Performance

Merck & Earnings & Revenue FAQ

What were MRK's earnings last quarter?

On Apr 29, 2021, Merck & (NYSE: MRK) reported Q1 2021 earnings per share (EPS) of $1.26, up 0.79% year over year. Total Merck & earnings for the quarter were $3.18 billion. In the same quarter last year, Merck &'s earnings per share (EPS) was $1.27.

What was MRK's earnings growth in the past year?

As of Q3 2021, Merck &'s earnings has grown -30.15% year over year. This is 44.94 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 14.79%. Merck &'s earnings in the past year totalled $7.03 billion.

What was MRK's revenue last quarter?

On Apr 29, 2021, Merck & (NYSE: MRK) reported Q1 2021 revenue of $12.08 billion up 0.19% year over year. In the same quarter last year, Merck &'s revenue was $12.06 billion.

What was MRK's revenue growth in the past year?

As of Q3 2021, Merck &'s revenue has grown -0.13% year over year. This is 13.45 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 13.32%. Merck &'s revenue in the past year totalled $48.02 billion.
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.